Literature DB >> 12372929

Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C.

Edwin Ten Boekel1, Piet Bartels.   

Abstract

Abnormally short activated partial thromboplastin times (APTTs) are associated with an increased risk of thrombotic disorders. We have examined the status of coagulation activity in subjects with short APTTs. In addition, the presence of the thrombotic risk factors G1691A-factor V, G20210A-prothrombin gene mutation and factor VIII coagulant activity (FVIII:C) was determined. Plasma levels of TAT, F1+2, D-dimer and FVIII:C were markedly higher in subjects with short APTTs compared with subjects with normal APTTs. APTTs were inversely related to TAT, F1+2, D-dimer and FVIII:C levels. The prevalence of G1691A-factor V and G20210A-prothrombin gene mutation between the group with short APTTs and the control group was not significantly different. Hence, these gene polymorphisms do not contribute to the increased risk of thrombosis associated with short APTTs. In conclusion, short APTTs are indicative of marked coagulation activity and elevated FVIII:C levels. Elevated FVIII:C levels may play a pathogenic role in the increased risk of thrombosis associated with abnormally short APTTs. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372929     DOI: 10.1159/000065217

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  10 in total

Review 1.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

2.  Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice.

Authors:  Kellie R Machlus; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

3.  Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values.

Authors:  Ying Zhao; Jie Zhang; Juanwen Zhang; Jianping Wu
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

4.  Exercise induced hypercoagulability, increased von Willebrand factor and decreased thyroid hormone concentrations in sled dogs.

Authors:  Anne K H Krogh; Pernille Legind; Mads Kjelgaard-Hansen; Louise Bochsen; Annemarie T Kristensen
Journal:  Acta Vet Scand       Date:  2014-02-07       Impact factor: 1.695

5.  Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.

Authors:  Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Thromb J       Date:  2015-01-23

6.  Evaluation of Potential Clinical Surrogate Markers of a Trauma Induced Alteration of Clotting Factor Activities.

Authors:  Manuel Burggraf; Arzu Payas; Carsten Schoeneberg; Alexander Wegner; Max Daniel Kauther; Sven Lendemans
Journal:  Biomed Res Int       Date:  2016-06-28       Impact factor: 3.411

7.  [Treatment of sepsis-induced coagulopathy : Results of a Germany-wide survey in intensive care units].

Authors:  Thomas Schmoch; Thorsten Brenner; Andrea Becker-Pennrich; Ludwig Christian Hinske; Markus A Weigand; Josef Briegel; Patrick Möhnle
Journal:  Anaesthesist       Date:  2021-02-08       Impact factor: 1.041

8.  16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Authors:  Hannah Cohen; Maria J Cuadrado; Doruk Erkan; Ali Duarte-Garcia; David A Isenberg; Jason S Knight; Thomas L Ortel; Anisur Rahman; Jane E Salmon; Maria G Tektonidou; David J Williams; Rohan Willis; Scott C Woller; Danieli Andrade
Journal:  Lupus       Date:  2020-10       Impact factor: 2.911

9.  System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings.

Authors:  Steve Kitchen; Moniek de Maat; Michael Nagler; Robert Jones; Anna Lowe; John Burden; Kai Groneberg; Gergely Rozsnyai
Journal:  Blood Coagul Fibrinolysis       Date:  2020-10       Impact factor: 1.061

10.  [Practice of pharmaceutical thrombosis prophylaxis and anticoagulation in patients with sepsis and pre-existing anticoagulation or heparin-induced type II thrombocytopenia-Results of a nationwide survey in German intensive care units].

Authors:  Thomas Schmoch; Thorsten Brenner; Andrea Becker-Pennrich; Ludwig Christian Hinske; Markus A Weigand; Josef Briegel; Patrick Möhnle
Journal:  Anaesthesist       Date:  2021-08-05       Impact factor: 1.041

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.